In the past 12 months, Cybin has expanded the psychedelic organization to more than 55 employees across four countries and has established partnerships with over 50 participants in the psychedelic industry.

The company has reached several key milestones this past year, proving the psychedelic industry is growing every year. Cybin was granted the U.S. Patent and Trademark Office, CYB004 (deuterated psychedelic tryptamine) for the treatment of anxiety disorders and FDA approvals for the company’s co-funded investigator-initiated phase 2 clinical trial. Using the EMBARK psychedelic facilitator training program, the trial is designed to evaluate psychedelic-assisted psychotherapy to treat frontline clinicians experiencing COVID-related distress.

Cybin has synthesized a new psilocybin drug called CYB003 for medical use in the UK. Cybin announced positive CYB003 data showing significant advantages compared to oral psilocybin for the treatment of mental health disorders, including a 50% reduction in variability, a 50% reduction in dose, a 50% shorter time to onset and nearly double brain penetration. Cybin included receiving a grant for a psychedelic treatment clinic at Lenox Hill Hospital, part of the largest healthcare system in New York State and in 2021 was granted a schedule I manufacturing license from the U.S. Drug Enforcement Agency for its Boston-area research lab, which will allow the company to expand its companies research and development.